Cargando…
Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma
OBJECTIVES: The aim of this study is to assess the course and management of poorly differentiated bladder urothelial carcinoma (UC), including plasmacytoid UC (PUC), in our local area. Although bladder cancer is relatively common, PUC is a rare and aggressive subtype with a poor prognosis that is st...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988797/ https://www.ncbi.nlm.nih.gov/pubmed/35475149 http://dx.doi.org/10.1002/bco2.108 |
_version_ | 1784683042033369088 |
---|---|
author | Lockhart, Kathleen King, Simon Grant, Alexander McLeod, Nicholas Tiu, Albert |
author_facet | Lockhart, Kathleen King, Simon Grant, Alexander McLeod, Nicholas Tiu, Albert |
author_sort | Lockhart, Kathleen |
collection | PubMed |
description | OBJECTIVES: The aim of this study is to assess the course and management of poorly differentiated bladder urothelial carcinoma (UC), including plasmacytoid UC (PUC), in our local area. Although bladder cancer is relatively common, PUC is a rare and aggressive subtype with a poor prognosis that is still poorly understood. MATERIALS AND METHODS: A retrospective assessment of all poorly differentiated high‐grade UC over the last 15 years (2005–2020) in the Hunter New England area was completed. In total, 37 patients were included, and PUC variant was compared with the remaining poorly differentiated UC. RESULTS: Of the included cases, eight were PUC, nine squamous variant, two neuroendocrine, and one sarcomatoid. Overall, 23 cases proceeded to cystectomy, 15 had chemotherapy (six neoadjuvant), and 11 had radiation therapy. In the PUC subgroup, three had metastatic disease at diagnosis (37.5%). Of the three PUC patients who underwent cystectomy, all were upstaged. Two PUC cases had adjuvant chemotherapy, and one case had radiation. Within the follow‐up period, the PUC group had a cause‐specific mortality of 50% with a mean survival in these patients of 202 days, compared with 37.9% cause‐specific mortality with survival of 671.55 days (p = 0.23) in all other undifferentiated UC cases; 5‐year cause‐specific mortality with Kaplan–Meier analysis was estimated at 26% compared with 59%, respectively (p = 0.058). CONCLUSION: Poorly differentiated UC is demonstrated to have a poor prognosis with a high mortality rate, particularly when PUC is present. Given the rarity of these variants, further studies are necessary to explore the impact of current treatment options. |
format | Online Article Text |
id | pubmed-8988797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89887972022-04-25 Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma Lockhart, Kathleen King, Simon Grant, Alexander McLeod, Nicholas Tiu, Albert BJUI Compass Original Articles OBJECTIVES: The aim of this study is to assess the course and management of poorly differentiated bladder urothelial carcinoma (UC), including plasmacytoid UC (PUC), in our local area. Although bladder cancer is relatively common, PUC is a rare and aggressive subtype with a poor prognosis that is still poorly understood. MATERIALS AND METHODS: A retrospective assessment of all poorly differentiated high‐grade UC over the last 15 years (2005–2020) in the Hunter New England area was completed. In total, 37 patients were included, and PUC variant was compared with the remaining poorly differentiated UC. RESULTS: Of the included cases, eight were PUC, nine squamous variant, two neuroendocrine, and one sarcomatoid. Overall, 23 cases proceeded to cystectomy, 15 had chemotherapy (six neoadjuvant), and 11 had radiation therapy. In the PUC subgroup, three had metastatic disease at diagnosis (37.5%). Of the three PUC patients who underwent cystectomy, all were upstaged. Two PUC cases had adjuvant chemotherapy, and one case had radiation. Within the follow‐up period, the PUC group had a cause‐specific mortality of 50% with a mean survival in these patients of 202 days, compared with 37.9% cause‐specific mortality with survival of 671.55 days (p = 0.23) in all other undifferentiated UC cases; 5‐year cause‐specific mortality with Kaplan–Meier analysis was estimated at 26% compared with 59%, respectively (p = 0.058). CONCLUSION: Poorly differentiated UC is demonstrated to have a poor prognosis with a high mortality rate, particularly when PUC is present. Given the rarity of these variants, further studies are necessary to explore the impact of current treatment options. John Wiley and Sons Inc. 2021-08-27 /pmc/articles/PMC8988797/ /pubmed/35475149 http://dx.doi.org/10.1002/bco2.108 Text en © 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Lockhart, Kathleen King, Simon Grant, Alexander McLeod, Nicholas Tiu, Albert Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title | Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title_full | Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title_fullStr | Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title_full_unstemmed | Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title_short | Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
title_sort | outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988797/ https://www.ncbi.nlm.nih.gov/pubmed/35475149 http://dx.doi.org/10.1002/bco2.108 |
work_keys_str_mv | AT lockhartkathleen outcomesofpoorlydifferentiatedandplasmacytoidvariantbladderurothelialcarcinoma AT kingsimon outcomesofpoorlydifferentiatedandplasmacytoidvariantbladderurothelialcarcinoma AT grantalexander outcomesofpoorlydifferentiatedandplasmacytoidvariantbladderurothelialcarcinoma AT mcleodnicholas outcomesofpoorlydifferentiatedandplasmacytoidvariantbladderurothelialcarcinoma AT tiualbert outcomesofpoorlydifferentiatedandplasmacytoidvariantbladderurothelialcarcinoma |